Devonyu/iStock by way of Getty Pictures
Guardant Well being (NASDAQ:GH) shares slid 5% whereas rival Actual Sciences (NASDAQ:EXAS) inventory rose 3% in morning buying and selling Wednesday within the wake of reports that the FDA had scheduled an advisory committee assembly to debate approval of Guardant’s Defend blood take a look at for the detection of colorectal most cancers.
Guardant introduced the information after market shut on Tuesday. The FDA committee assembly is tentatively scheduled for March 28.
Actual Sciences markets a preferred at-home colon most cancers screening take a look at referred to as Cologuard. The corporate can be creating a blood take a look at to display for colorectal most cancers, according to its website.
Shares of Actual Sciences rose 8% on Tuesday forward of the FDA information, whereas Guardant shares rose 3%.